What are the antibiotic prophylaxis recommendations for a patient with immunoglobulin A (IgA) nephropathy?

Antibiotic Prophylaxis for IgA Nephropathy

When treating IgA nephropathy patients with systemic glucocorticoids, antimicrobial prophylaxis against Pneumocystis jirovecii is mandatory, along with antiviral prophylaxis in hepatitis B carriers. 1

When Antimicrobial Prophylaxis is Required

Antibiotic prophylaxis is not a routine component of IgA nephropathy management itself. Rather, it becomes essential only in the specific context of immunosuppressive therapy:

Systemic Glucocorticoid Therapy Context

When Nefecon (targeted-release budesonide) is unavailable and you opt for systemic glucocorticoids, the KDIGO 2025 guideline explicitly recommends:

• Reduced-dose systemic glucocorticoid regimen: Methylprednisolone 0.4 mg/kg/day (maximum 32 mg/day) for 2 months, followed by tapering by 4 mg/day each month for a total of 6-9 months 1

• Combined with antimicrobial prophylaxis against Pneumocystis jirovecii 1

• Antiviral prophylaxis in hepatitis B carriers 1

• Gastroprotection and bone protection according to national guidelines 1

Key Clinical Algorithm

Step 1: Determine if patient requires immunosuppressive therapy (at risk of progressive kidney function loss with proteinuria >0.5 g/day)

Step 2: If Nefecon is available and approved → Use Nefecon (no specific antimicrobial prophylaxis mentioned for this agent) 1

Step 3: If Nefecon unavailable → Use systemic glucocorticoids with mandatory Pneumocystis jirovecii prophylaxis 1

Step 4: Screen for hepatitis B; if carrier → Add antiviral prophylaxis 1

Important Caveats

• The antimicrobial prophylaxis requirement is specific to systemic glucocorticoid use, not to IgA nephropathy itself
• This reflects the immunosuppressive burden of prolonged corticosteroid therapy, which increases infection risk
• The guideline does not specify the exact antimicrobial agent (e.g., trimethoprim-sulfamethoxazole vs. alternatives), deferring to local institutional protocols for Pneumocystis prophylaxis
• Rapidly progressive IgAN requiring cyclophosphamide and glucocorticoids would similarly require antimicrobial prophylaxis, following ANCA-associated vasculitis protocols 1

What Does NOT Require Prophylaxis

The following IgA nephropathy treatments do not require routine antimicrobial prophylaxis:

• RAS inhibitors (ACEi/ARB) 1
• SGLT2 inhibitors 1
• Sparsentan (dual endothelin-angiotensin receptor antagonist) 1
• Targeted-release budesonide (Nefecon) - no specific prophylaxis mentioned 1